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Abstract
Background: Chronic kidney disease (CKD) is associated with endothelial dysfunctions thus prompting links
between microcirculation (MC), inflammation and major cardiovascular risk factors.
Purpose of the study: We have previously reported that siRNA-silencing of CD40 (siCD40) reduced atherosclerosis
(ATH) progression. Here, we have deepened on the effects of the siCD40 treatment by evaluating retrospectively, in
stored kidneys from the siCD40 treated ApoE−/− mice, the renal microcirculation (measured as the density of
peritubular capillaries), macrophage infiltration and NF-κB activation.
Methods: Kidneys were isolated after 16 weeks of treatment with the anti-CD40 siRNA (siCD40), with a scrambled
control siRNA (siSC) or with PBS (Veh. group). Renal endothelium, infiltrating macrophages and activated NF-κB in
endothelium were identified by immunohistochemistry, while the density of stained peritubular capillaries was
quantified by image analysis.
Results: ATH was associated with a reduction in renal MC, an effect reversed by the anti-CD40 siRNA treatment
(3.8 ± 2.7% in siCD40; vs. 1.8 ± 0.1% in siSC; or 1.9 ± 1.6% in Veh.; p < 0.0001). Furthermore, siCD40 treatment reduced
the number of infiltrating macrophages compared to the SC group (14.1 ± 5.9 cells/field in siCD40; vs. 37.1 ± 17.8
cells/field in siSC; and 1.3 ± 1.7 cells/field in Veh.; p = 0.001). NF-κB activation also peaked in the siSC group, showing
lower levels in the siCD40 and Veh. groups (63 ± 60 positive cells/section in siCD40; vs. 152 ± 44 positive cells/
section in siSC; or 26 ± 29 positive cells/section in veh.; p = 0.014). Lastly, serum creatinine was also increased in the
siCD40 (3.4 ± 3.3 mg/dL) and siSC (4.6 ± 3.0 mg/dL) groups when compared with Veh. (1.1 ± 0.9 mg/dL, p = 0.1).
Conclusions: Anti-CD40 siRNA therapy significantly increased the density of peritubular capillaries and decreased
renal inflammation in the ATH model. These data provide a physiological basis for the development of renal
diseases in patients with ATH. Furthermore, our results also highligth renal off-target effects of the siRNA treatment
which are discussed.
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Background
Atherosclerosis (ATH) is associated with a systemic in-
flammatory state characterized by the activation of endo-
thelial and blood cells and by an increase in the
plasmatic concentration of inflammatory factors [1]. In-
flammation is also involved in renal injury and may trig-
ger compensatory mechanisms to offset tissue injury-
dependent ATH lesions, suggesting a close interrelation
among them [2]. In addition, there are evidences of the
existence of a physiological link between renal microcir-
culation (MC) and ATH progression [3], supporting the
relevance of kidney in the pathogenesis of ATH. In this
sense, it has been described that kidneys have a key
regulatory role in the renin-angiotensing system (RAS)
[4], and that the blockade of RAS reduces both the de-
velopment of cardiovascular and renal diseases [5]. Thus,
the activation of inflammatory pathways could promote
kidney injury and accelerate the progression of athero-
sclerotic lesions.
Endothelium is a key regulator of vascular homeosta-
sis, with autocrine and paracrine functions, and it is
known that activation of the endothelium in the renal
microvascular network cause inflammation and the acti-
vation of the Nuclear Factor-κB (NF-κB) pathway [6].
Kidneys are highly sensitive to hypoxia because of their
high oxygen demand from tubular cells and the low oxy-
gen tensions present in the medulla [7]. Insults to
endothelial-cells (EC) activate oxidative systems, such as
the NADPH oxidase complex, that produce hydrogen
peroxide which subsequently causes oxidative stress [8].
Furthermore, this stimulates the phosphorylation of NF-
κB, which leads to the activation of EC, the upregulation
of chemotactic factors and adhesive receptors, and to
the recruitment of leukocytes [8]. In this sense, it its
known that NF-κB activates many of the genes involved
in the inflammatory response network that are pivotal in
the pathogenesis of vascular injury [9], and that activated
NF-κB could have a role in the progression of kidney
diseases [10], thus suggesting that NF-κB activation
could be the physiological link among vascular injury
and the development of renal diseases.
CD40/CD40L interaction has a critical role in ATH
pathogenesis since this stimulates the NF-κB pathway
and upregulates the expression of proinflamatory and
proatherogenic genes [11]. Endothelial cell expression of
CD40 is increased by acute and chronic inflammatory
stimuli [12], and CD40/CD40L signalling has been impli-
cated in inflammation-enhanced microvascular throm-
bosis [13]. On the other hand, it has been reported that
ablation of CD40, either by silencing with an anti-CD40-
specific siRNA or by genetic deletion (as CD40−/−
ApoE−/− double knockout mice), caused a significant re-
duction in the area of atherosclerotic plaques, also asso-
ciated with a decrease of inflammation [14, 15].
The renal effects of the siCD40 treatment have been
tested by our group in rat models of renal transplant-
ation and in experimental models of Lupus Nephritis,
which showed an improvement in the renal function in
a dose dependent manner as well as the preservation of
the renal architecture [16, 17]. Nevertheless, a number
of concerns have been raised on the off-target side ef-
fects of siRNA therapies likely caused by the activation
of the innate immune system through the RNA-sensing
pattern recognition (PRRS) of siRNAs [18]. Here, we
deepened on the functional relationships among kidneys
and aorta by studying the renal microvascular network
and the degree of renal inflammation in ApoE−/− mice
treated with the siCD40 therapy. We have also addressed
the off-target side effects of siRNA therapies, and here
we show that this resulted in a significant increase in
renal inflammation in the ApoE−/− mice, with the subse-
quent impact on renal function.
Results
Anti-CD40 siRNA treatment increased microcapillar
density in the kidneys of treated mice
We have previously shown that silencing of the costimu-
latory receptor CD40 with a specific siRNA (siCD40
group) ameliorated progression of experimental ATH in
the ApoE−/− model mouse when compared with control
animals treated with a scrambled-sequence siRNA (siSC
group) or with vehicle (Veh. group) [15]. We hypothe-
sized that ATH progression could be also associated to a
reduction in renal microcirculation, and here we show
that the siCD40 therapy impacted on the renal microca-
pillar density, measured as the number of PECAM-1
positive cells per optical field at a 200x magnification. As
can be seen in Fig. 1a–d, the endpoint of ATH progres-
sion after 16 weeks of treatment showed similar values
for PECAM-1 positive cells in the two control groups,
treated with vehicle only (1.9 ± 1.6% of positive cells, n =
10 mice) or with the siSC (1.8 ± 0.1% of positive cells,
n = 5), while the value for the mice treated with the
siCD40 was significantly higher (3.8 ± 2.7% of positive
cells, n = 10; p < 0.0001).
SiCD40 treatment increased macrophage infiltration and
NF-κB activation in the kidneys of treated mice
In our previous work, we described a macrophage
miRNA/mRNA signature for ATH progression in
siCD40 treated mice [15]. Since siRNA duplexes are
known to be potent activators of the innate immune sys-
tem [19] we aimed to study possible “off-target” effects
of the therapy by focusing in macrophage and inflamma-
tory responses. To achieve this objective, we measured
macrophage infiltration (as F4/80-positive cells) and NF-
κB activation (as NF-κB-p65 positive nuclear staining)
by IHC in sections of the kidneys of mice treated with
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the control vehicle, the control siSC or with the siCD40
for 16 weeks. Figure 2a–d clearly shows that kidneys
from mice treated with the two siRNAs (siSC and
siCD40) showed higher values of infiltrating F4/80-posi-
tive cells when compared with the vehicle control. Mice
from the siSC group showed the highest levels of macro-
phage infiltration, 37.1 ± 17.8 F4/80 positive cells/section
(Fig. 2b, d) vs.1.2 ± 1.7% F4/80 positive cells/section for
animals treated with the vehicle only (Fig. 2a, d). Macro-
phages were predominantly located in tubular capillaries
and around the glomeruli in the siSC group, and glom-
erular lesions were characterized by a foam cell appear-
ance (Fig. 2b). Treatment with the siCD40 partially
reversed the increase seen in the SC group (14.1 ± 5.9
F4/80 positive cells/section; p = 0.001), but did not re-
cover the vehicle control values (Fig. 2c, d).
On the other hand, activation of NF-κB has been asso-
ciated to the progression of renal tubulointerstiticial le-
sions in experimental proteinuric nephropathies and in
the development of glomerulonephritis [10]. Following
to macrophage infiltration, we measured NF-κB activa-
tion (by counting nuclear NF-κB-p65-positive cells) in
the same experimental model (Fig. 3a–d). Similarly, to
the effect described for F4/80-positive cells, nuclear NF-
κB-p65 peaked in the siSC group, with values of 152 ±
44 positive cells/section (Fig. 3b, d), when compared
values measured in the control group treated with the
vehicle only which showed 26 ± 29 positive cells/section
Fig. 1 Anti-CD40 siRNA treatment increases microcapillar density in kidneys from ApoE-deficient mice. Representative images of the anti-
CD31(PCAM-1)/haematoxylin staining of kidney sections from ApoE−/− mice treated with: a control vehicle (Veh), b a control sequence-scrambled
siRNA (siSC), or c the anti-CD40 siRNA (siCD40), at 200x magnification (Scale bars are 100 µm). To increase contrast and facilitate visualization,
endothelial cells (EC) were stained in false red with ImageJ. G shows the renal glomeruli and the arrows some EC. d Box-plot showing the
proportion of vessel area density per kidney section (see Material and Methods for details on the measurement). Each diagram represents the
median, quartiles and outliers. The colored box represents the interquartile range that contains 50% of the values. The whiskers are lines that
extended from the box to the highest and lowest values, excluding outliers. A line across the box represents the median value. Kruskal Wallis test
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(Fig. 3a, d). Enhanced NF-κB-p65 activation was clearly
detected in tubules, EC and inflammatory infiltrated cells
in the siSC group (Fig. 3b), and as for macrophage infil-
tration, the effect of NF-κB activation was partially re-
versed by the treatment with the siCD40 up to 63 ± 60
positive cells/section (p = 0.014), although in this case
the inter-individual variability was very high (Fig. 3c, d).
Lastly, we also measured serum creatinine as a meas-
ure of renal function. The two groups treated with siR-
NAs (siCD40 and siSC) showed increased levels of
serum creatinine when compared with the vehicle con-
trol group, (3.4 ± 3.3 mg/dL in the siCD40 treated group,
n = 10; 4.6 ± 3.0 mg/dL in the siSC group, n = 5; 1.1 ± 0.9
mg/dL in vehicle group, n = 10; p = 0.1), suggesting the
existence of off-target side renal effects. On the other
hand, cholesterol levels did not show significant changes
among groups (1193 ± 310 mg/dL in siCD40 treated
group, n = 10; 1159 ± 250 mg/dL in siSC group, n = 5;
1387 ± 475 mg/dL in vehicle group, n = 10; p = ns).
In summary, we previously reported the efficacy of the
therapeutic use of an anti-CD40-specific short interfer-
ence RNA (siRNA) to reduce atherosclerotic lesions in a
murine model [15]. Here, we show that the kidneys from
mice treated with the siCD40 showed a significantly
higher microcapillar density, as the number of CD31/
PECAM1 positive endothelial cells per section, than the
control mice. On the other hand, our work has also
highlighted unwanted side-effects of the siRNA therapy
Fig. 2 Anti-CD40 siRNA treatment increases macrophage infiltration in the kidneys of treated mice. Representative images of F4-80/haematoxylin
staining of kidney sections from ApoE−/− mice treated with: a control vehicle (veh), b a control sequence-scrambled siRNA (siSC), or c the anti-
CD40 siRNA (siCD40), at 200x magnification (Scale bars are100 μm). G shows the renal glomeruli and a number of positive cells are marked by
arrows. d Box-plot showing the number of F4/80+ cells per kidney section. Each diagram represents the median, quartiles and outliers. The
colored box represents the interquartile range that contains 50% of the values. The whiskers are lines that extended from the box to the highest
and lowest values, excluding outliers. A line across the box represents the median value. Kruskal Wallis test
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which affected to the renal inflammatory homeostasis
(increased macrophage infiltration and NF-κB activation)
and to the renal function (increased serum creatinine).
Discussion
Our group is interested in the cardiovascular complica-
tions of CKD patients. We previously demonstrated that
treating Apolipoprotein E-deficient (ApoE−/−) mice with
a siRNA against the costimulatory receptor CD40
(siCD40) ameliorated ATH progression, and here we
have deepened on the physiological mechanisms in-
volved in the siCD40 action in the context of a func-
tional “aorta-kidney axis”. We have shown that the
siCD40 treatment impacted on the renal microcapillar
density and resulted in an activation of the innate im-
mune response in mice treated for 16 weeks, over the
values found in the control groups treated with vehicle
(PBS) or with a scrambled-sequence siRNA (siSC) also
during 16 weeks.
The Atherosclerosis-prone, C57BL/6 J ApoE−/− mice
model is characterized by a poor liver lipoprotein clear-
ance of diet-derived chylomicrons and liver-derived
VLDL remnants with accumulation of cholesterol ester-
enriched particles in blood [20]. Hypercholesterolemia
(HC) can impair both the function and structure of large
and small vessels, thus damaging target organs, as well
Fig. 3 Anti-CD40 siRNA treatment increases NF-κB activation in the kidneys of treated mice. NF-κB-p65 Representative images of NF-κB-p65/
haematoxylin staining of kidney sections from ApoE−/− mice treated with: a control vehicle (veh), b a control sequence-scrambled siRNA (siSC), or
c the anti-CD40 siRNA (siCD40), at 200x magnification (Scale bars are100 μm). A number of positive cells are marked by arrows. G shows the renal
glomeruli, PT shows some proximal tubules characterized by large cells with an apical brush border (not all nuclei are visible in the cross-section)
and DT shows some distal tubules with smaller cells. d Box-plot showing the number of NF-κB-p65 + cells per kidney section. Each diagram
represents the median, quartiles and outliers. The colored box represents the interquartile range that contains 50% of the values. The whiskers are
lines that extended from the box to the highest and lowest values, excluding outliers. A line across the box represents the median value. Kruskal
Wallis test
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as to increase renal oxidative stress [2]. In our previous
study in ApoE−/− mice, progression of ATH was associ-
ated with increased local inflammation in plaques from
aorta, while systemic CD40 silencing was associated with
a reduction in the number of plaques infiltrating macro-
phages, intimal CD40+ cells and NF-κB expressing cells,
but the kidneys from the treated mice could not be ana-
lysed [15]. In this extension study, we have observed that
renal MC density was higher in mice treated with the
siCD40 than in the controls (siSC or Veh groups), sug-
gesting that the degeneration of the vascular walls asso-
ciated to a marked increase in total plasma cholesterol
could be prevented by silencing CD40. In this sense, it
has been proposed that endothelial dysfunction, vascular
remodelling and the loss of the renal microvessels played
a prominent role in inducing renal injury associated with
major cardiovascular risk factor [21], with the CD40/
CD40L system contributing to the enhanced micro-
vascular thrombosis associated with models of inflam-
mation and with CD40 deficiency protecting against
thrombosis [13].
ApoE−/− mice display renal injuries characterized by
glomerular macrophage infiltration with accumulation of
foam cells, foci of mesangiolysis, focal intracapilary lipid
deposits and foam cell transformation of arterial smooth
muscle cells in glomerular hiliar arterioles [22]. In this
work, the two groups of siRNA-treated animals, the
siCD40 and the siSC group showed a significantly higher
infiltration by macrophages, as well as an overactivation
of the NF-κB pathway when compared with the group of
animals treated with the vehicle only. This increase in
inflammatory markers was further associated with a loss
of renal function as measured by increased levels of
serum creatinine (3.4 ± 3.3 mg/dL in the siCD40 and
4.6 ± 3.0 mg/dL in SC vs. 1.1 ± 0.9 mg/dL in Veh.; p =
0.1), suggesting the existence of kidney off-target effects
for the siRNA therapy. Interestingly, the siSC-treated
group showed higher macrophage infiltration and a peak
of NF-κB activation when compared with the siCD40, a
fact suggesting a protective effect by the specific siCD40
sequence, likely by interfering the inflammatory cascade.
The existence of unwanted side-effects is hindering
the therapeutic potential of siRNAs. RNA Interference
(RNAi)-based therapies are slowly permeating the clin-
ical practice, specially to treat undruggable targets [23],
although much work has yet to be done regarding their
stability, bioavailability, safety and specificity, target val-
idation, tissue specificity, and transfection/transduction
efficiency [24, 25] prior to considering them as estab-
lished therapies for different diseases, from cancer to
CVD [26, 27]. Among this “to-do” list, the question of
specificity is one of the most important and difficult to
resolve, because siRNAs are promiscuous by nature and
a single siRNA may target more than one mRNA (even
through imperfect base-pairing) to cause off-target silen-
cing [28]. To reduce these unwanted effects a number of
strategies have been devised, as reducing the concentra-
tion of siRNA used [28], modifying the structure of the
siRNA backbone [29], introducing chemical modifica-
tions to the seed sequence [30] or introducing sequential
information and structural features of the sequences
flanking the seed sequence [31]. Furthermore, a number
of algorithms [32, 33] and databases [34, 35] have been
established to facilitate the development of more specific
siRNAs with less off-targets effects.
Interestingly, our control siRNA (siSC), which had the
same base composition of the siCD40 but in a random
sequence and was designed to highlight sequence-
dependent effects, also showed significant off-target ef-
fects, such as the infiltration by macrophages and the
overactivation of the NF-κB pathway, suggesting a role
for the siRNA backbone itself, its modifications or the
delivery vehicle, in the generation of the unwanted ef-
fects. In this sense, it is known that siRNAs can activate
innate immunity (see [36] for a recent review), through
the binding of double-stranded RNA by Toll-like Recep-
tors (TLR), a family of innate-recognition receptors that
recognize molecular patterns associated with microbial
pathogens and activate the NF-κB pathway [37]. Further-
more, several studies have demonstrated that the im-
mune response to siRNA is cell type-dependent, due to
the selective expression of TLRs. SiRNAs stimulate
monocytes and myeloid dendritic cells, through TLR8,
to produce pro-inflammatory cytokines or to activate
plasmacytoid dendritic cells, and through TLR7, to pro-
duce type 1 interferons [38]. In addition, it has been re-
ported that an unmodified, naked, anti-caspase-3 siRNA
is able to pass through the glomerular filtration barrier
into the urine [39], aggravating renal graft injury [40]
and suggesting a potential mechanism of renal toxicity.
On the other hand, although we have herein reported an
increase in macrophage infiltration and NF-κB activation
in the kidneys of ApoE−/− mice treated with siSC or
siCD40 versus mice treated with vehicle, in a previous
work using the same siCD40 in the NZB/NZW F1 mice
model of lupus nephritis we did not notice any evidence
of activation of TLR3, TLR4 or TLR9 [16]. Furthermore,
our group has also described that the systemic injection
of siCD40 in rat models of renal transplantation did not
activate the local innate immune response, as no
changes in TLR3 or NF-κB expression were detected
[17]. These results suggest that stimulation of the innate
immune system by siRNAs might be also dependent of
the microenvironment or on the animal genetic
background.
Lastly, this study has highlighted unwanted off-target
side effects of the otherwise efficient anti-CD40 siRNA
therapy, and more strikingly of the scrambled sequence
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siRNA used as control in the animal experiments. Off-
target side effects are one of the major obstacles for
siRNA therapy [38], since it has been demonstrated that
siRNAs can even induce significant changes in cell via-
bility in a target-independent fashion [41]. In this con-
text, our results call for a more careful consideration of
the impact of siRNAs on the innate immune system
prior to establish highly efficient siRNA therapies.
Clearly, more work on the range of siRNA dosages ad-
ministrated, on the vehicles used for administration as
well as in the administration frequency will be needed to
reduce the off-target effects of siRNA therapies and to
guarantee their efficacy and safety. On the other hand,
the discovery of the off-target effects of the siSC con-
trol is, certainly, a flaw on the preclinical use of spe-
cific siRNAs in experimental animal models since this
is a very popular control, although it remains to be
studied whether the effects here described were
kidney-specific or part of a more systemic effect and
some doubts were previously casted on its utility as
experimental control [42].
Conclusions
ATH was associated with a reduction in renal microca-
pillary density, an effect reversed by the immunomodula-
tory effect of anti-CD40 siRNA treatment. However,
careful consideration of the impact of siRNA loads on
the innate immune system as well as in the delivery is
required to reduce the unwanted off-target side effects
and to guarantee the safety of siRNA therapies.
Methods
Animal models
In this work we used kidney tissue samples from 25 fe-
male ApoE−/− mice (Jackson Laboratory, Charles River,
Wilmington, MA, USA) from a previous study [15].
Briefly, 8 weeks old mice were treated twice weekly with
an intraperitoneal administration of 50 μg of siRNA
against CD40 (siCD40), of a scrambled siRNA (SC) as
control, or with phosphate buffered saline as vehicle
(Veh) for 16 weeks. Mice were euthanized by isoflurane
anaesthesia after 16 weeks of treatment (SC/24w, n = 5;
siCD40/24w, n = 10; and Veh, n = 10). To accelerate ath-
erosclerosis, mice were fed with a western diet that con-
tained 0.2% cholesterol, and provided 42% calories as fat
(TD.88137; Harlan-Tekland, Madison, WI, USA). All
animal studies were in accordance with EU guidelines
on animal care and the protocols were approved by the
ethics committee for animal research of the University
of Barcelona-HUB.
Materials, siRNAs and antibodies
The sequences, preparation and use of the small inter-
ference RNAs (siRNAs) used in this work have been
already described [16, 43]. The commercial synthetic
siRNAs (siCD40 sense 5′-GUGUGUUACGUGCA
GUGACUU, siCD40 antisense 5′-AAGUCACUGC
ACGUAACACACUG, siSC sense 5′-ACUACAAGAC
UCGUGACCAUU, siSC antisense 5′-UGGUCACGAG
UCUUGUAGUUU, all from Mycrosynth, Switzerland)
included stabilizing phosphorothioate backbone and
2′-O-methyl sugar modifications, as well as a choles-
terol molecule added at the 3′ end of the sense
strand with a pyrolidine linker to facilitate uptake and
internalization.
For the immunochemical work, we used a rat mono-
clonal antibody against F4/80 (Hycult biotech, Uden,
NL), a rabbit polyclonal anti-NF-κB-p65 (anti-phospho-
S536, Ab86299, Abcam, Cambridge, UK), and a goat
polyclonal anti-CD31/PECAM-1 (platelet-endothelial
cell adhesion molecule-1) antibody (M-20, sc-1506,
Santa Cruz Biotechnology, Santa Cruz, CA). As a sec-
ondary antibody we used a goat anti-rat IgG2 (Novus Bi-
ologicals, Littleton, CO), a biotinylated horse anti-goat
IgG (BA-9500, Vector, Burlingame, CA) or a Vectastain
Elite ABC kit for rabbit antibodies (PK-4001-NB, Vector
Laboratory, Burlingame, CA).
Immunohistochemistry
Here, we have studied the microcirculation and in-
flammation in the kidneys of the ApoE−/− model
mice by using standard procedures of Immunohisto-
chemistry. Formalin-fixed, paraffin-embedded kidneys
were sliced at 3 μm, stained with the rat monoclonal
against F4/80, or with the rabbit polyclonal anti-NF-
κB-p65 (Abcam, Cambridge, UK) and counterstained
with haematoxylin to make nuclei evident. Human
parotid glands or ganglions were used as positive
controls. Isotype controls were performed by staining
uniquely with antibody buffer supplemented with ir-
relevant immunoglobulines of the same isotype, spe-
cies and concentration as the primary antibodies
(ThermoFisher, Rockford, IL USA). Negative controls
were performed by omitting primary antibodies in
the staining. Macrophage infiltration was assessed by
counting the total number of F4/80+ cells by field in
a total of 5 kidney sections, while activated endothe-
lial cells were detected after NF-κB-p65 nuclear
staining. Positively stained cells were counted at ×
200 magnifications by capturing images directly from
a RGB camera (ProgRes CF scan) attached to a light
microscope (NIKON E800). Micro vessel density was
assessed by using a systematic random sampling
method on microscope kidney sections previously
stained for the pan-endothelial marker [44]. We se-
lected five regions of interest (ROIs), on each whole-
slide image, on which we measured the density of
peritubular vessels per 200x area in tissue sections.
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We applied digital tools to automate image quantifi-
cation with ImageJ v1.48. Results were expressed as
the proportion of vessel area density per kidney
section [44].
Statistical analysis
Macrophage infiltration and endothelial cells with nu-
clear NF-κB were measured as the mean ± standard devi-
ation. Differences in cell infiltration and vessel area
density between in mice treated with siCD40, scrambled
or vehicle were compared by the Kruskal-Wallis test. A
p < 0.05 value was considered statistically significant. P
values were corrected for the number of variables com-
pared according to the Bonferroni method. Statistical
analysis was performed using the SPSS 20.0 software
(SPSS Inc. Chicago, IL).
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